A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

(2017) M. Thomas et al.   INVESTIGATIONAL NEW DRUGS

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

(2017) Christian Manegold et al.   Journal of Thoracic Oncology

Abstract A02: Imprime PGG modulates the myeloid component of the tumor microenvironment to coordinate an antitumor immune response

(2016) Kathryn Fraser et al.   CANCER RESEARCH

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

(2016) C. E. Halstenson et al.   INVESTIGATIONAL NEW DRUGS

Abstract B019: Imprime PGG, a soluble β-glucan, binds to and activates dendritic cells resulting in enhanced T cell priming, expansion, and cytokine production

(2016) Ross B. Fulton et al.   Cancer Immunology Research

Abstract A128: Imprime PGG, a novel, clinical-stage pathogen associated molecular pattern, modulates MDSC function, facilitating a coordinated antitumor immune response

(2016) Kathryn Fraser et al.   Cancer Immunology Research

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

(2016) Anissa S. H. Chan et al.   PLoS One

Abstract 5034: Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity

(2015) Steven M. Leonardo et al.   CANCER RESEARCH

Abstract LB-225: Imprime PGG modulates the function of monocyte-derived M2 macrophages and dendritic cells to drive T-cell expansion

(2015) Anissa SH Chan et al.   CANCER RESEARCH

Abstract LB-228: Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells

(2015) Nandita Bose et al.   CANCER RESEARCH

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Gregory A. Masters et al.   JOURNAL OF CLINICAL ONCOLOGY

Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

(2015) David P. Carbone et al.   Journal of Thoracic Oncology

Abstract A3: Imprime PGG triggers a coordinated anti-cancer immune response in concert with anti-angiogenic antibodies, re-polarizing the immune microenvironment to suppress tumor growth

(2015) Kathryn Fraser et al.   MOLECULAR CANCER THERAPEUTICS

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

(2014) B. Besse et al.   ANNALS OF ONCOLOGY

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype

(2014) Anissa SH Chan et al.   Journal for ImmunoTherapy of Cancer

Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer

(2013) Julie R. Brahmer   JOURNAL OF CLINICAL ONCOLOGY

What Lies Within: Novel Strategies in Immunotherapy for Non-Small Cell Lung Cancer

(2013) P. M. Forde et al.   ONCOLOGIST

Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent

(2013) Nandita Bose et al.   Frontiers in Immunology

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived  -glucans

(2011) C. Qi et al.   BLOOD

Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome

(2011) Frances A. Shepherd et al.   Journal of Thoracic Oncology

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Yeast-derived β-glucan in Conjunction With Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models

(2009) Wangjian Zhong et al.   JOURNAL OF IMMUNOTHERAPY

Yeast-Derived  -Glucan Augments the Therapeutic Efficacy Mediated by Anti-Vascular Endothelial Growth Factor Monoclonal Antibody in Human Carcinoma Xenograft Models

(2008) C. Salvador et al.   CLINICAL CANCER RESEARCH